Franklin, Tenn. – November 3, 2009 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three and nine months ended September 30, 2009, on Thursday, November 5, 2009 after the close of the market. The Company will host a conference call and audio webcast to discuss its third quarter financial results and product development programs and business activities at 4:30 EST the same day.

The conference call may be accessed on November 5, 2009 by dialing 888.679.8040 (passcode:72254521). The international dial in number is 617.213.4851, and the same passcode applies. You may also pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=P7CH63T8X.

A live webcast of the conference call will be available on the Investor Relations section of BioMimetic’s website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.

About BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. is developing and commercializing regenerative protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of the rhPDGF-BB platform technology. Additionally, the Company has both completed and ongoing clinical trials with its product candidates Augment and Augment Injectablein multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's previously approved product and lead product candidates all combine recombinant protein therapeutics (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration.

GEM 21S is a trademark of Luitpold Pharmaceuticals, Inc., who now owns those products and markets GEM 21S through its Osteohealth Company in the United States and Canada.

For further information, contact Kearstin Patterson, corporate communications, at 615-236-4419.